Cargando…
Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since...
Autores principales: | Martinez, Maria J., Lyles, Rolando D.Z., Peinetti, Nahuel, Grunfeld, Alex M., Burnstein, Kerry L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495664/ https://www.ncbi.nlm.nih.gov/pubmed/37705955 http://dx.doi.org/10.1016/j.isci.2023.107681 |
Ejemplares similares
-
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022) -
In silico analysis of deleterious single nucleotide polymorphisms in human BUB1 mitotic checkpoint serine/threonine kinase B gene
por: Akhoundi, Fatemeh, et al.
Publicado: (2016) -
BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis
por: Zhou, Xiaolei, et al.
Publicado: (2022) -
Serine/Threonine Protein Kinase STK16
por: Wang, Junjun, et al.
Publicado: (2019) -
Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens
por: Lyles, Rolando D. Z., et al.
Publicado: (2023)